Эффективность и безопасность ламотриджина при биполярном аффективном расстройстве


А.В. Ушкалова (1), Е.А. Ушкалова (2)

(1) Клиника «Душевное здоровье», Москва; (2) Кафедра общей и клинической фармакологии РУДН, Москва
Ламотриджин является эффективным препаратом лечения биполярного аффективного расстройства с преобладающей антидепрессивной активностью. Он эффективен при остром эпизоде депрессии, но наиболее большое значение имеет для длительной поддерживающей терапии пациентов с преобладающей депрессивной симптоматикой. Преимущество ламотриджина перед другими нормотимиками, особенно при длительном применении, в его высокой безопасности, в т.ч. для детей, лиц пожилого возраста и беременных женщин.

Литература


1. Karanti A., Kardell M., Lundberg U., Landén M. Changes in mood stabilizer prescription patterns in bipolar disorder. J. Affect Disord. 2016;195:50–6.

2. Kessing L.V., Vradi E., Andersen P.K. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar. Disord. 2016;18(2):174–82.

3. Chang C.M., Wu C.S., Huang Y.W., et al. Utilization of Psychopharmacological Treatment Among Patients With Newly Diagnosed Bipolar Disorder From 2001 to 2010. J. Clin. Psychopharmacol. 2016;36(1):32–44.

4. Ketter T.A., Manji H.K., Post R.M. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J. Clin. Psychopharmacol. 2003;23(5):484–95.

5. Hahn C.G., Gyulai L., Baldassano C.F., et al. 2004. The current understanding of lamotrigine as a mood stabilizer. J. Clin. Psychiatry, 65:791–804.

6. Бурчинский С.Г. Антиконвульсанты нового поколения и стандарты монотерапии эпилепсии. Международный неврол. журн. 2007;6(16).

7. Muck-Seler D., Sagud M., Mustapic M., et al. The effect of lamotrigine on platelet monoamine oxidase type B activity in patients with bipolar depression. Prog. Neuropsychopharmacol Biol. Psychiatry. 2008;32(5):1195–98.

8. Shim S.E., Mansari M., Blier P. Modulation of the antidepressant-like effects of sustained administration of carisbamate and lamotrigine on monoaminergic systems: electrophysiological studies in the rat brain. J. Pharmacol. Exp. Ther. 2013;347:487–96.

9. Ng F.Hallam K., Lucas N., Berk M. The role of lamotrigine in the managementof bipolar disorder. Neuropsychiatr. Dis. Treat. 2007;3(4):463–74.

10. Chowdhury D. New drugs for the treatment of epilepsy: a practical approach. J. Assoc. Physicians India. 2013;61(Suppl. 8):19–23.

11. Мосолов С.Н., Костюкова Е.Г., Цукарзи Э.Э. Федеральные клинические рекомендации по диагностике и лечению биполярного аффективного расстройства 2013. http://psychiatr.ru/news/183.

12. Rosa A.R., Fountoulakis K., Siamouli M., Gonda X., Vieta E. Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. CNS Neurosci Ther. 2011;17(3):167–77.

13. Bowden C.L., Singh V. Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. Expert Opin. Pharmacother. 2012;13(17):2565–71.

14. Vieta E., Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013;27(7):515–22.

15. Azorin J.M., Belzeaux R., Cermolacce M., Kaladjian A., et al. Recommendations for the treatment of mixed episodes in current guidelines. Encephale. 2013;39(Suppl. 3):S185–87.

16. Balon .R, Riba M. Should women of childbearing potential be prescribed valproate? a call to action. J. Clin. Psychiatry. 2016;77(4):525–26.

17. Kaplan Y.C., Abdelkader N. Valproate prescribing trends for non-epilepsy indications in women of reproductive age warrants effective measures and increased surveillance. Seizure. 2016;40:13–4.

18. Fountoulakis K.N., Kasper S., Andreassen O., et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur. Arch. Psychiatry Clin. Neurosci. 2012;262(Suppl. 1):1–48.

19. Calabrese J.R., Huffman R.F., White R.L., et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar. Disord. 2008;10:323–33.

20. Geddes J.R., Calabrese J.R., Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br. J. Psychiatry. 2009;194:4–9.

21. Mitchell P.B., Hadzi-Pavlovic D., Evoniuk G., et al. Factor analysis in bipolar depression and response to lamotrigine. CNS Spectr. 2013;18(4):214–24.

22. Srivastava S., Ketter T.A. Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects. Clin. Ther. 2011;33(12):B40–84:4–9.

23. Vázquez G.H., Holtzman J.N., Tondo L., Baldessarini R.J. Efficacy and tolerability of treatments for bipolar depression. J. Affect. Disord. 2015;183:258–62.

24. Swartz H.A., Thase M.E. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J. Clin. Psychiatry. 2011;72(3):356–66.

25. Vieta E., Locklear J., Günther O., et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J. Clin. Psychopharmacol. 2010;30:79–590.

26. Brown E.B., McElroy S.L., Keck P.E.Jr., et al. (2006) A 7-week, randomized, double- blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J. Clin. Psychiatry 67:1025–33.

27. Amann B., Born C., Crespo J.M., Pomarol-Clotet E., McKenna P. Lamotrigine: when and where does it act in affective disorders? A systematic review. J. Psychopharmacol. 2010;10:1289–94.

28. Price A.L., Marzani-Nissen G.R. Bipolar disorders: a review. Am. Fam. Physician. 2012;85(5):483–93.

29. Pfennig A., Bschor T., Falkai P., Bauer M. The diagnosis and treatment of bipolar disorder: recommendations from the current s3 guideline. Dtsch. Arztebl. Int. 2013;110(6):9–100.

30. Woo Y.S., Lee J.G., Jeong J.H., et al. Korean Medication Algorithm Project for Bipolar Disorder: third revision. Neuropsychiatr. Dis. Treat. 2015;11:49–506.

31. Goodwin G.M., Bowden C.L., Calabrese J.R., et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J. Clin. Psychiatry. 2004;65:432–41.

32. Grunze H., Vieta E., Goodwin G., Bowden C., Licht R.W., Moller H.J., Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2009 on the treatment of bipolar depression. World J. Biol. Psychiatry. 2009;10(2):85–116.

33. Beynon S., Soares-Weiser K., Woolacott N., Duffy S., Geddes J.R. Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J. Psychopharmacol. 2009;23:574–91.

34. Vieta E., Gunther O., Locklear J., Ekman M., Miltenburger C., Chatterton M.L., Åström M., Paulsson B. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int. J. Neuropsychopharmacol. 2011;14(8):1029–49.

35. Goldsmith D.R., Wagstaff A.J., Ibbotson T., Perry C.M. Spotlight on lamotrigine in bipolar disorder. CNS Drugs. 2004;18(1):63–7.

36. Goldberg J.F., Calabrese J.F., Saville B.R., et al. Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. J. Clin. Psychiatry. 2009;79(9):1273–80.

37. Bowden C.L., Asnis G.M., Ginsberg L.D., et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug. Saf. 2004;27:173–84.

38. French J.A., Gazzola D.M. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther. Adv. Drug. Saf. 2011;2(4):141–58.

39. Murru A., Popovic D., Pacchiarotti I., et al. Management of adverse effects of mood stabilizers. Curr. Psychiatry Rep. 2015;17(8):603.

40. Bowden C.L., Calabrese J.R., Ketter T.A., et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am. J. Psychiatry. 2006;163(7):1199–201.

41. Sachs G., Bowden C., Calabrese J.R., et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord. 2006;8(2):175-81.

42. Chuang Y.C., Chuang H.Y., Lin T.K., et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia. 2012;53(1):120–28.

43. Daban C., Martínez-Arán A., Torrent C., et al. Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results. J. Clin. Psychopharmacol. 2006;26(2):178–81.

44. Gil-Nagel A., López-Muñoz F., Serratosa J.M., et al. Effect of lamotrigine on sexual function in patients with epilepsy. Seizure. 2006;15(3):142–49.

45. National Collaborating Centre for Mental Health. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. London (UK): National Institute for Health and Care Excellence (NICE); 2014;58. (Clinical guideline; no. 185).

46. Seo H.J., Chiesa A., Lee S.J., et al. Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin. Neuropharmacol. 2011; 34(1):39–47.

47. Wang X.Q., Xiong J., Xu W.H., et al. Risk of a lamotrigine-related skin rash: current meta-analysis and postmarketing cohort analysis. Seizure. 2015;25:52–61.

48. Lee S.A., Lee H.W., Heo K., et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure. 2011;20(1):49–54.

49. Aldenkamp A.P., Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav. 2001;2:85–91.

50. Blum D., Meador K., Biton V., et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology. 2006;67:400–6.

51. Pavuluri M.N., Passarotti A.M., Mohammed T., et al. Enhanced working and verbal memory after lamotrigine treatment in pediatric bipolar disorder. Bipolar. Disord. 2010;12(2):213–20.

52. Keck P.E., Jr,. McElroy S.L., Strakowski S.M., et al. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol. Bull. 1997;33:87–9.

53. Zhao Z., Okusaga O.O., Quevedo J., et al. The potential association between obesity and bipolar disorder: A meta-analysis. J. Affect Disord. 2016;202:120–3.

54. Vancampfort D., Sienaert P., Wyckaert S., et al. The Metabolic Syndrome Is Associated with Self-Reported Physical Complaints in Patients with Bipolar Disorder. Psychiatr. Danub. 2016;28(2):139–45.

55. Vancampfort D., Correll C.U., Galling B., et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15(2):166–74.

56. Pérez-Piñar M., Mathur R., Foguet Q., et al. Cardiovascular risk factors among patients with schizophrenia, bipolar, depressive, anxiety, and personality disorders. Eur. Psychiatry. 2016;35:8–15.

57. Gonda X., Kalman J., Dome P., Rihmer Z. Changes in quality of life and work function during phase prophylactic lamotrigine treatment in bipolar patients: 6 month, prospective, observational study. Neuropsychopharmacol. Hung. 2016;18(1):57–67.

58. Suzuki H., Gen K. Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer’s disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial. Psychogeriatrics. 2015;15(1):32–7.

59. Bailly D. Pharmacological treatment of bipolar disorder in children and adolescents. Encephale. 2016.

60. Greil W., Häberle A., Schuhmann T., et al. Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. Swiss Med. Wkly. 2013;143:w13772.

61. Gerard E.E., Meador K.J. Managing Epilepsy in Women. Continuum (Minneap Minn). 2016;22(1 Epilepsy):204–26.

62. Khan S.J., Fersh M.E., Ernst C., et al. Bipolar Disorder in Pregnancy and Postpartum: Principles of Management. Curr. Psychiatry Rep. 2016;18(2):13.

63. Costoloni G., Pierantozzi E., Goracci A., Bolognesi S., Fagiolini A. Mood stabilisers and pregnancy outcomes – a review. Psychiatr. Pol. 2014;48(5):865–87.

64. Meador K., Reynolds M.W., Crean S., et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81(1):1–13.

65. Nguyen H.T., Sharma V., McIntyre R.S. Teratogenesis associated with antibipolar agents. Adv. Ther. 2009;26(3):281–94.

66. Tomson T., Battino D., Bonizzoni E., Craig J., Lindhout D., Sabers A., Perucca E., Vajda F., EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–17.

67. Dolk H., Wang H., Loane M., et al. Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies. Neurology. 2016;86(18):1716–25.

68. Forsberg L., Wide K. Long-term consequences after exposure to antiepileptic drugs in utero. Ther. Adv. Drug. Saf. 2011;2(5):227–34.


Об авторах / Для корреспонденции


А.В. Ушкалова – к.м.н., врач-психиатр клиники «Душевное здоровье», Москва


Похожие статьи


Бионика Медиа